ClinicalTrials.gg
CompletedNCT01237457Updated Mar 20, 2023

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

A Phase 2 interventional study of 177Lu-DOTATATE in Neuroendocrine Tumors, sponsored by Ebrahim S Delpassand. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Ebrahim S Delpassand · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2016, 10 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing lutetium Lu 177 dotatate in Neuroendocrine Tumors — 3 open to participants now, 6 under way, none of them phase 3. lutetium Lu 177 dotatate · Neuroendocrine Tumors.

Enrollment
4th of 23
143 · median 31
Started
2010
the only one that year
Phase 2
10 of 23
2 open now
Registered
1st of 23
by date
Lead sponsor
1 of 23
Ebrahim S Delpassand

Among the 23 studies testing lutetium Lu 177 dotatate in Neuroendocrine Tumors, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 10 in phase 2, and was the 1st registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

3 of the 23 studies testing lutetium Lu 177 dotatate in Neuroendocrine Tumors are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lutetium Lu 177 dotatate

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing lutetium Lu 177 dotatate in Neuroendocrine Tumors, or all of them as a file.
02

Study summary

This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non-radioiodine avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small cell lung, Carcinoid, and pancreatic islet cell malignancies).

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven Gastroenteropancreatic (GEP tumors including bronchial carcinoids)
  • Presence of somatostatin-receptors on the known tumor lesions demonstrated by OctreoScan within 6 months of the first dose of radiolabelled octreotate therapy. The uptake on the OctreoScan should be at least as high as normal liver uptake on planar imaging.
  • greater than 12 weeks.
  • Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dL and a measured (or measured using plasma clearance methods, not gamma camera based) of ≥ 50ML/min.
  • (Hgb) concentration ≥ 5.5 mmol/L (≥ 8.9 g/dL); WBC ≥ 2*109/L (2000/mm3); ≥ 100*109/L (100*103/mm3).
  • Total ≤ 3X UNL.
  • Serum Albumin > 30g/L or serum albumin ≤ 30g/L but normal .
  • All patients must have a performance status of at least 60%
  • Patients must be greater than 18 years of age. Patients younger than 18 years will be presented to FDA for compassionate use on a case by case basis

Exclusion criteria

Exclusion Criteria:

  • Possible surgery with curative intent.
  • Surgery, radiotherapy, chemotherapy or other therapy within 3 months of the start of therapy.
  • Patients with known unless these have been treated and stabilized for at least 6 months prior to study start. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to study start.
  • Uncontrolled congestive heart failure.
  • Any subject who is taking concomitant medications which decrease renal function (such as aminoglycoside antibiotics).
  • Any subject receiving therapy with somatostatin analogues, unless the dose has been stable for at least 3 months prior to the first cycle in this study and the disease status during these 4 months has been documented by modified RECISTS criteria as described in this study
  • Any subject receiving therapy with short acting somatostatin analogues in whom these analogues cannot be interrupted for 12 hours before and 12 hours after the administration of the radio labelled somatostatin analogues, or any subject who receives therapy with long-acting somatostatin analogues in whom these analogues cannot be interrupted for at least 6 weeks before the administration of the radio labeled somatostatin analogues, unless the uptake on the Octreoscan during continued somatostatin analogue medication is at least as high as normal liver uptake on planar imaging.
  • In patients with unusual hematological parameters, including an increased MCV (>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up.
  • Subjects with another significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study.
  • Prior radiation therapy to more than 25% of the bone marrow.
  • Female patients who are pregnant, lactating or women of not willing to practice effective techniques during the study period and for 60 days (10 half lives of 177Lu after the last treatment, or male patients who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 60 days after the last treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Treatment

    Patients with somatostatin receptor-expressing neuroendocrine neoplasms will receive up to 200 mCi of 177Lu-DOTATATE every 6-11 weeks, preferably 6-9 weeks to a cumulative dose of 800 mCi.

    Drug: 177Lu-DOTATATE

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free survival

    Overall response will be determined by Progression Free Survival (PFS). PFS will be calculated as a function of time from start of therapy to time of overall disease progression. Patients will be censored at the date of last contact

    Time frame: one year after completion of last treatment cycle

Secondary outcomes

  1. Dose limiting toxicity

    Patients will be monitored for dose toxicity according to NCI guidelines

    Time frame: one year after completion of the fourth cycle of treatment

07

Study locations

1 site
  • Excel Diagnostics and Nuclear Oncology Center
    Houston, Texas 77042, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Nov 2016, 72 months.

Of 85 non-industry phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 83. This study's 72 months is above that.

Counting every sponsor, half of 98 studies reached it within 65 months; a quarter within 42 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2010
First posted
Nov 9, 2010
StartActual
Oct 27, 2010
Primary completionActual
Nov 17, 2016
CompletionActual
Jul 25, 2017
Results delay requested
Mar 14, 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01237457
Lead sponsor
Ebrahim S Delpassand
Collaborators
Excel Diagnostics and Nuclear Oncology Center
Responsible party
Ebrahim S Delpassand (Chairman and Medical Director, Excel Diagnostics and Nuclear Oncology Center) — Sponsor-investigator
First posted
Nov 9, 2010
Start date
Oct 27, 2010
Primary completion
Nov 17, 2016
Completion
Jul 25, 2017
Last update
Mar 20, 2023

Study contacts

Ebrahim S Delpassand, M.D
principal investigator · Excel Diagnostics and Nuclear Oncology Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium Lu 177 dotatate

Start the discussion